CRIS Current Research Information System

RASCHI, EMANUEL
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.701
AS - Asia 8.009
EU - Europa 6.340
AF - Africa 564
SA - Sud America 557
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 6
Totale 24.214
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.568
SG - Singapore 2.521
CN - Cina 2.353
IT - Italia 1.607
GB - Regno Unito 1.445
VN - Vietnam 1.258
DE - Germania 818
HK - Hong Kong 721
SE - Svezia 553
IN - India 434
BR - Brasile 430
RU - Federazione Russa 341
NL - Olanda 282
KR - Corea 275
FR - Francia 249
IE - Irlanda 231
CI - Costa d'Avorio 203
TG - Togo 160
UA - Ucraina 147
JP - Giappone 110
FI - Finlandia 106
ZA - Sudafrica 106
CA - Canada 89
EE - Estonia 81
BG - Bulgaria 78
AT - Austria 73
ID - Indonesia 72
AR - Argentina 58
CH - Svizzera 53
ES - Italia 51
JO - Giordania 50
BE - Belgio 49
PL - Polonia 41
TR - Turchia 40
MX - Messico 31
PT - Portogallo 31
AU - Australia 28
BD - Bangladesh 24
SC - Seychelles 24
EC - Ecuador 23
HR - Croazia 21
NG - Nigeria 21
UZ - Uzbekistan 18
TW - Taiwan 16
LT - Lituania 15
GR - Grecia 14
SA - Arabia Saudita 14
CL - Cile 13
PH - Filippine 13
CO - Colombia 12
TH - Thailandia 12
IL - Israele 11
EG - Egitto 10
MA - Marocco 10
CZ - Repubblica Ceca 9
KE - Kenya 9
MY - Malesia 9
NZ - Nuova Zelanda 9
TN - Tunisia 9
IQ - Iraq 8
IR - Iran 8
RO - Romania 8
DK - Danimarca 7
PK - Pakistan 7
BA - Bosnia-Erzegovina 6
LB - Libano 6
DZ - Algeria 5
KZ - Kazakistan 5
PE - Perù 5
PY - Paraguay 5
SI - Slovenia 5
UY - Uruguay 5
VE - Venezuela 5
SM - San Marino 4
AE - Emirati Arabi Uniti 3
EU - Europa 3
HU - Ungheria 3
MT - Malta 3
OM - Oman 3
RS - Serbia 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
AZ - Azerbaigian 2
CY - Cipro 2
DM - Dominica 2
DO - Repubblica Dominicana 2
HN - Honduras 2
KH - Cambogia 2
KW - Kuwait 2
LK - Sri Lanka 2
NO - Norvegia 2
SV - El Salvador 2
YE - Yemen 2
AL - Albania 1
BF - Burkina Faso 1
BO - Bolivia 1
BW - Botswana 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
Totale 24.200
Salva come PNG Salva come JPEG
Città #
Singapore 1.617
Southend 1.209
Ashburn 912
Fairfield 849
Hong Kong 689
Hefei 656
Chandler 651
Bologna 472
Dong Ket 391
Santa Clara 391
Wilmington 388
Woodbridge 387
Seattle 370
Princeton 318
Houston 300
Cambridge 298
Beijing 295
Seoul 268
Ann Arbor 254
Boardman 245
Ho Chi Minh City 243
Dublin 226
Abidjan 203
Lomé 159
Los Angeles 158
Dallas 154
Hanoi 152
Redmond 140
Westminster 99
Berlin 95
Milan 93
Nanjing 87
New York 86
Buffalo 85
Tokyo 85
Padova 80
Sofia 77
London 73
Redondo Beach 71
Helsinki 67
Saint Petersburg 66
Jinan 63
Rome 61
Turin 61
Jacksonville 60
Bengaluru 59
Florence 58
Munich 58
San Diego 56
Falls Church 51
Jakarta 51
Amman 50
Shenyang 48
The Dalles 48
Shanghai 47
São Paulo 47
Bremen 46
Brussels 46
Vienna 44
Frankfurt am Main 41
Medford 39
Guangzhou 38
Modena 38
Hebei 37
Toronto 37
Bern 36
Chicago 36
Des Moines 35
Nuremberg 33
Nanchang 32
Changsha 31
Hangzhou 31
Tianjin 31
Boydton 30
Zhengzhou 30
Jiaxing 26
San Francisco 26
Falkenstein 25
Haiphong 25
Phoenix 25
Council Bluffs 24
Dearborn 24
Mülheim 24
Verona 24
Biella 23
Biên Hòa 23
Paris 23
Yubileyny 22
Amsterdam 21
Bühl 21
Da Nang 21
Porto 21
Warsaw 21
Turku 20
Cesena 19
Lappeenranta 19
Moscow 19
Tongling 19
Abeokuta 17
Istanbul 17
Totale 15.517
Salva come PNG Salva come JPEG
Nome #
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. 469
ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance 453
ROCCA cohort study: Nationwide results on safety of Gam-COVID-Vac vaccine (Sputnik V) in the Republic of San Marino using active surveillance 311
Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems 294
Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS) 276
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system 271
hERG-related drug toxicity and models for predicting hERG liability and QT prolongation 232
Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies 229
Appropriateness of Proton Pump Inhibitor (PPI) prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy 229
Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems 225
Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals 213
Advancements in drug development for diarrhea-predominant irritable bowel syndrome 204
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. 196
Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database. 194
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 186
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System 185
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System 184
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 182
Antimicrobials and the Risk of Torsades de Pointes. The Contribution from Data Mining of the US FDA Adverse Event Reporting System 182
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System 180
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: beyond bleeding complications 179
Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones: A Disproportionality Analysis of the US FDA Adverse Event Reporting System Database. 175
Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis 175
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct 174
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database 173
Pattern of drug use among preterm neonates: Results from an Italian neonatal intensive care unit 170
Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System 169
Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping 166
Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database 166
The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project 165
Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System 164
Clinically important drug-drug interactions in poly-treated elderly outpatients: A campaign to improve appropriateness in general practice 163
Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development 160
Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system 159
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System 158
Pro-arrhythmic potential of oral antihistamines (H1): Combining adverse event reports with drug utilization data across Europe 156
Drug-induced Kounis syndrome: A matter of pharmacovigilance 155
Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis 154
Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection 151
Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis 150
Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing 148
Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region 147
Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey 146
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study 144
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE? 144
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies 143
Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres 143
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS 142
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System 142
Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling 142
Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction 142
Prevalence and determinants of long-term utilization of antidepressant drugs: A retrospective cohort study 140
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People 139
Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology 139
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance 139
QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus 138
New regulation on medical devices made of substances: Opportunities and challenges for pharmacological and toxicological research 137
Recurrence of pericarditis after influenza vaccination: a case report and review of the literature 135
Antimicrobial-induced torsades de pointes: towards risk stratification by data mining of the FDA Adverse Event Reporting System. 134
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment 134
Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure 133
The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. 133
Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials 132
The hERG K+ channel: target and antitarget strategies in drug development. 132
Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. 132
The beta3-adrenoceptor as a therapeutic target: current perspectives. 131
Association between the use of proton pump inhibitors and cardiovascular events: A note of caution 131
Stroke, Migraine and Triptans: From Bedside to Bench 130
Role of drugs and devices in patients at risk of sudden cardiac death. 130
Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective 129
Apparato Gastroenterico 128
Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. 127
Balancing the Need for Personalization of QT Correction and Generalization of Study Results: Going Beyond Thorough QT Studies 127
Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry 127
Infarto del miocardio, edema maculare e fratture associate ai glitazoni: analisi del database di segnalazione spontanea FDA_AERS 126
Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies 126
Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease 126
Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. 126
Macrolides and Torsadogenic Risk: Emerging Issues from the FDA Pharmacovigilance Database 125
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System 125
The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia 125
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems 125
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations 124
COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety 123
Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: Insight from a pharmacovigilance study 121
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase 120
Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review 120
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 120
Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden. 119
Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system 119
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 118
Impact of notoriety bias on reporting of pancreatitis with antidiabetics: the case of exenatide 118
Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews 118
No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase 117
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase 117
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement 115
Identification of Drug Interaction Adverse Events in Patients With COVID-19: A Systematic Review 115
Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period. 114
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors 113
Symmetrical cutaneous rash in two women. 112
Totale 15.944
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.481
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 295
Totale 76.776
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.394 0 0 0 0 0 80 80 138 190 104 135 667
2021/20222.983 301 89 140 125 239 184 182 242 154 147 642 538
2022/20233.487 382 404 265 413 246 231 167 257 517 171 276 158
2023/20241.432 91 178 166 235 118 181 62 110 43 94 86 68
2024/20255.077 285 692 551 289 616 271 339 216 156 342 298 1.022
2025/20265.956 1.134 1.151 1.173 877 1.303 318 0 0 0 0 0 0
Totale 24.828